OSTX

Dollar change -1.17
Percentage change -28.40	%

Peers: MRK PFE JNJ AMGN BMY GILD LLY REGN BIIB VRTX

Index	-	P/E	-	EPS (ttm)	-	Insider Own	33.53%	Shs Outstand	21.18M	Perf Week	-40.64%
Market Cap	62.66M	Forward P/E	-	EPS next Y	-	Insider Trans	-0.23%	Shs Float	14.12M	Perf Month	-15.23%
Income	-	PEG	-	EPS next Q	-0.14	Inst Own	0.75%	Short Float	0.38%	Perf Quarter	-6.05%
Sales	-	P/S	-	EPS this Y	-	Inst Trans	0.16%	Short Ratio	0.14	Perf Half Y	-
Book/sh	-0.03	P/B	-	EPS next Y	-	ROA	-	Short Interest	0.05M	Perf Year	-
Cash/sh	0.09	P/C	33.69	EPS next 5Y	-	ROE	-	52W Range	1.58 - 7.00	Perf YTD	-31.07%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-57.86%	Beta	-
Dividend TTM	-	Quick Ratio	0.76	Sales past 5Y	-	Gross Margin	-	52W Low	86.71%	ATR (14)	1.01
Dividend Ex-Date	-	Current Ratio	0.76	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	39.54	Volatility	39.96% 29.90%
Employees	-	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	14.67
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-46.24%	Payout	-	Rel Volume	4.32	Prev Close	4.12
Sales Surprise	-100.00%	EPS Surprise	-50.00%	Sales Q/Q	-	Earnings	Nov 15 BMO	Avg Volume	376.19K	Price	2.95
SMA20	-32.38%	SMA50	-9.00%	SMA200	-10.64%	Trades		Volume	1,624,923	Change	-28.40%

Jan-17-25 08:35AM	OS Therapies price target raised to $15 from $8 at Maxim (TipRanks) -28.40%
Jan-15-25 09:17AM	OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma (Business Wire)
Jan-02-25 11:16AM	OS Therapies to Attend the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-31-24 03:38PM	OS Therapies Announces Closing of $6 Million Private Placement (Business Wire) -8.94%
Dec-26-24 12:04PM	OS Therapies Partners With B2i Digital to Engage With Biotech Investors Online (NewMediaWire) +33.29%
09:40AM	Loading…
Dec-25-24 09:40AM	OS Therapies to sell 1.5M units at $4.00 in private placement (TipRanks)
Dec-24-24 09:32AM	OS Therapies Announces Pricing of $6 Million Private Placement (Business Wire)
Nov-15-24 09:47AM	OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Nov-04-24 07:00AM	OS Therapies to Present at The Spartan Capital Investor Conference (Business Wire)
Oct-30-24 08:51AM	Join OS Therapies Exclusive Live Investor Webinar and Q&A Session on October 30 (Business Wire)
Oct-28-24 04:44PM	OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors (Business Wire) -8.69%
Oct-24-24 08:46AM	OS Therapies to Present at the LD Micro Main Event XVII (Business Wire)
Oct-17-24 09:22AM	OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit (Business Wire)
Oct-03-24 08:00AM	OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient Visit (Business Wire)
Sep-13-24 08:09AM	OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates (Business Wire)
07:59AM	Loading…
Sep-12-24 07:59AM	Transforming Cancer Therapy Stocks to Watch In The Oncology Sector (News Direct)
Sep-11-24 08:15AM	OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models (ACCESSWIRE) -6.40%
Sep-05-24 08:22AM	OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference (Business Wire)
Aug-29-24 07:53AM	OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose (Business Wire)
Aug-22-24 08:00AM	OS Therapies Appoints Borys Shor, PhD to ADC Advisory Board (Business Wire)
06:00AM	OS Therapies Clarifies CUSIP of Common Stock (Business Wire)
Aug-21-24 05:00AM	The Future of Medicine: Key Biotech Stocks to Watch (News Direct)
Aug-19-24 08:30AM	OS Therapies Accepted Into Johnson & Johnson Innovation - JLABS (Business Wire) +14.66%
Aug-15-24 08:30AM	OS Therapies Reports Second Quarter 2024 Financial Results (ACCESSWIRE) +12.03%
Aug-09-24 09:00AM	OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE) +33.78%
Aug-06-24 08:35AM	OS Therapies Announces Osteosarcoma Scientific and Medical Advisory Board (ACCESSWIRE) +17.37%
Aug-02-24 08:55AM	OS Therapies Forms Osteosarcoma Patient Advocacy Advisory Board (Business Wire) +59.36%
Jul-31-24 06:21PM	OS Therapies Announces Pricing of its Initial Public Offering on NYSE American - Company to Trade under Symbol "OSTX" (Business Wire)
Jul-24-24 10:48AM	OS Therapies Announces Positive Safety Data from Phase 1 Clinical Trial of OST-HER2 in HER2-Expressing Breast Cancer and in Preclinical Efficacy in Models of Breast Cancer (Business Wire)
Jun-03-24 12:44PM	OS Therapies Announces Positive Clinical Update from Ongoing Phase 2b Clinical Trial in Resected, Recurrent Osteosarcoma (Business Wire)

OS Therapies, Inc. operates as a clinical stage biopharmaceutical company. It engages in identification, development, and commercialization of treatments for Osteosarcoma and other related diseases. The company was founded by Paul A. Romness on April 12, 2018 and is headquartered in Rockville, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Auerbach Shalom	10% Owner	Jan 15 '25	Sale	6.74	16,720	112,609	2,531,211	Jan 17 07:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OS Therapies Inc

Upgrade your FINVIZ experience